Impact of CPAP Treatment on Arterial Stiffness in Patients With T2DM and Newly Diagnosed Obstructive Sleep Apnoea

Nordsjaellands Hospital70 enrolled

Overview

The purpose of the trial is to investigate the effects of three months' treatment with a CPAP-device versus control group on change in arterial stiffness in type 2 diabetes (T2D) patients with newly detected Obstructive Sleep Apnoea (OSA).

Background: Obstructive sleep apnoea (OSA) is a common disorder characterised by recurrent episodes of apnoea or hypopnoea during sleep. OSA is associated with excessive daytime sleepiness and linked to increased cardiovascular morbidity and mortality. OSA can be alleviated with Continuous Positive Airway Pressure (CPAP) treatment. Cardiovascular disease is the major cause of decreased life expectancy, morbidity and reduced quality of life in patients with type 2 diabetes (T2D). Increased stiffness of the aorta has been associated with increased cardiovascular morbidity and mortality in diabetic patients. Previous studies have reported a much higher frequency of OSA in patients with obesity and T2D compared with non-diabetic subjects, and found that OSA was associated with arterial stiffness. However, whether CPAP treatment improves arterial stiffness and insulin sensitivity in T2D patients remain to be elucidated. Objective: To investigate the effects of three months' treatment with a CPAP-device versus sham CPAP on change in arterial stiffness in T2D patients with newly detected OSA. Design: Randomised, controlled, multicentre study of intervention with CPAP treatment versus control group. The treatment period is three months with a subsequent 9 months open extension. Patient population: 70 patients with T2D and newly diagnosed OSA recruited from Department of Cardiology, Nephrology and Endocrinology, Nordsjællands Hospital, Department of Endocrinology, Gentofte University Hospital, Department of Endocrinology and Internal Medicine, Aarhus University Hospital Nørrebrogade and Department of Internal Medicine, Silkeborg Sygehus. Intervention: CPAP treatment versus control group. Endpoints: Primary endpoint: Change in arterial stiffness measured by office carotid-femoral pulse wave velocity (cf-PWV) from start to end of 12 weeks intervention.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetes Obstructive Sleep Apnea

Interventions

CPAPDEVICE

CPAP intervention

ControlOTHER

Control

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 diabetes mellitus (WHO criteria) * Obstructive sleep apnea defined as apnoea-hypopnoea index (AHI) \> 15 diagnosed with ApneaLink+® measured within three months or less prior to visit 0. * Signed informed content. Exclusion Criteria: * Contraindications to CPAP treatment. * Treatment with CPAP within the last 6 months prior to visit 1. * Works in a transportation-related industry * C-peptide \< 300 pmol/l - measured less than 6 months prior to visit 0 * HbA1c:\< 7% or \>10% - both exclusive - at visit 0 * Changes in antidiabetic treatment during the last four weeks prior to visit 0. * Unstable bodyweight, i.e. \>5% change during the last three months prior to visit 0. * Other sleep breathing disorder

Locations (1)

Nordsjællands hospital

Hillerød, Denmark

RECRUITING

Outcomes

Primary Outcomes

Change in arterial stiffness measured by office carotid-femoral pulse wave velocity (cf-PWV) from start to end of 12 weeks intervention

Time frame: three month

Secondary Outcomes

Change from start to end of 13 weeks intervention in insulin sensitivity measured by hyperinsulinemic euglycemic clamp

Time frame: three month

Central Contacts

Anne Banghøj, MD

CONTACT

anne.margareta.banghoej@regionh.dk

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.